Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription


1 Acta Haematol
6 Ann Hematol
1 Biochem Biophys Res Commun
6 Blood
2 BMC Cancer
3 Bone Marrow Transplant
1 Cancer Lett
1 Int J Hematol
1 J Clin Oncol
1 J Virol
1 Leuk Lymphoma
4 Leuk Res
4 Leukemia
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Haematol

  1. JIN X, Jiang X, Li H, Shen K, et al
    Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria.
    Acta Haematol. 2024 Apr 16. doi: 10.1159/000538658.
    PubMed         Abstract available

    Ann Hematol

  2. THAU S, Poulsen CB, Brieghel C, Larsen MK, et al
    COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study.
    Ann Hematol. 2024 Apr 18. doi: 10.1007/s00277-024-05738.
    PubMed         Abstract available

  3. JEBANESAN DZP, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, et al
    Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.
    Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05742.
    PubMed         Abstract available

  4. LEOTTA S, Markovic U, Duminuco A, Mule A, et al
    Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
    Ann Hematol. 2024 Apr 13. doi: 10.1007/s00277-024-05725.
    PubMed         Abstract available

  5. FRANKE GN, Loewe G, Reiser M, Linde H, et al
    Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.
    Ann Hematol. 2024;103:1569-1575.
    PubMed         Abstract available

  6. NISCOLA P, Gianfelici V, Giovannini M, Piccioni D, et al
    Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
    Ann Hematol. 2024;103:1787-1788.

  7. SHUMILOV E, Mazzeo P, Ghandili S, Kunstner A, et al
    Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
    Ann Hematol. 2024;103:1587-1599.
    PubMed         Abstract available

    Biochem Biophys Res Commun

  8. SUZUKI S, Liu J, Sato Y, Miyake R, et al
    Fucosylation inhibitor 6-alkynylfucose enhances the ATRA-induced differentiation effect on acute promyelocytic leukemia cells.
    Biochem Biophys Res Commun. 2024;710:149541.
    PubMed         Abstract available


  9. WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al
    Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
    Blood. 2024;143:1616-1627.
    PubMed         Abstract available

  10. RENGA G, Nunzi E, Stincardini C, Pariano M, et al
    CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
    Blood. 2024;143:1628-1645.
    PubMed         Abstract available

  11. LAMBLE AJ, Rau RE
    IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
    Blood. 2024;143:1556-1557.

  12. CUNEO A, Ghia P
    Ibrutinib in CLL: benefit for all?
    Blood. 2024;143:1558-1559.

  13. BUFFET R
    How lipid coating soothes the gut in AML therapy.
    Blood. 2024;143:1559-1561.

  14. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
    Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
    Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564.
    PubMed         Abstract available

    BMC Cancer

  15. YI X, Zhan H, Lyu J, Du J, et al
    A chest CT-based nomogram for predicting survival in acute myeloid leukemia.
    BMC Cancer. 2024;24:458.
    PubMed         Abstract available

  16. WANG L, Zhao S, Wang Y, Liu J, et al
    UBE2C promotes the proliferation of acute myeloid leukemia cells through PI3K/AKT activation.
    BMC Cancer. 2024;24:497.
    PubMed         Abstract available

    Bone Marrow Transplant

  17. SHEN Y, Liu M, Shen D, Chu M, et al
    Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02280.

  18. DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
    Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.

  19. NAGLER A, Labopin M, Swoboda R, Schroeder T, et al
    Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplanta
    Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284.
    PubMed         Abstract available

    Cancer Lett

  20. SUN H, Xie Y, Wu X, Hu W, et al
    circRNAs as prognostic markers in pediatric acute myeloid leukemia.
    Cancer Lett. 2024;591:216880.
    PubMed         Abstract available

    Int J Hematol

  21. FUJITA H
    JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
    Int J Hematol. 2024 Apr 17. doi: 10.1007/s12185-024-03749.

    J Clin Oncol

  22. TOBIASSON M, Pandzic T, Illman J, Nilsson L, et al
    Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
    J Clin Oncol. 2024;42:1378-1390.
    PubMed         Abstract available

    J Virol

  23. PRAMONO D, Takeuchi D, Katsuki M, AbuEed L, et al
    FeLIX is a restriction factor for mammalian retrovirus infection.
    J Virol. 2024;98:e0177123.
    PubMed         Abstract available

    Leuk Lymphoma

  24. TINAJERO J, Ngo D, Zhang J, Tsai NC, et al
    High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
    Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506.

    Leuk Res

  25. HU X, Cao P, Wang F, Wang T, et al
    Alternative polyadenylation quantitative trait loci contribute to acute myeloid leukemia risk genes regulation.
    Leuk Res. 2024;141:107499.
    PubMed         Abstract available

  26. ZAD Z, Bonecker S, Wang T, Zalcberg I, et al
    Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models.
    Leuk Res. 2024;141:107502.

  27. BERTON G, Sedaki B, Collomb E, Benachour S, et al
    Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.
    Leuk Res. 2024;141:107500.
    PubMed         Abstract available

  28. ASHOURI K, Ginosyan AA, Chu M, Hom B, et al
    Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study.
    Leuk Res. 2024;141:107501.
    PubMed         Abstract available


  29. IYODA S, Yoshida K, Shoji K, Ito N, et al
    KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.
    Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02244.

  30. NORONHA N, Durette C, Cahuzac M, E Silva B, et al
    Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia.
    Leukemia. 2024 Apr 16. doi: 10.1038/s41375-024-02250.
    PubMed         Abstract available

  31. CURIK N, Laznicka A, Polivkova V, Krizkova J, et al
    Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
    Leukemia. 2024 Apr 13. doi: 10.1038/s41375-024-02248.

  32. MATSUI S, Ri C, Bolanos LC, Choi K, et al
    Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression.
    Leukemia. 2024 Apr 12. doi: 10.1038/s41375-024-02245.
    PubMed         Abstract available

    PLoS One

  33. KNOPPERS T, Haley CE, Bouhouita-Guermech S, Hagan J, et al
    From code to care: Clinician and researcher perspectives on an optimal therapeutic web portal for acute myeloid leukemia.
    PLoS One. 2024;19:e0302156.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.